A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer

por Beachler, Daniel C., Lamy, Francois-Xavier, Russo, Leo, Taylor, Devon H., Dinh, Jade, Yin, Ruihua, Jamal-Allial, Aziza, Dychter, Samuel, Lanes, Stephan, Verpillat, Patrice
Publicado 2020

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteer...

por Printz, Marie A., Dychter, Samuel S., DeNoia, Emanuel P., Harrigan, Rena, Sugarman, Barry J., Zepeda, Monica, Souratha, Jennifer, Kang, David W., Maneval, Daniel C.
Publicado 2020

1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccin...

por Thomas, S.J., Perez, J.L., Lockhart, S.P., Hariharan, S., Kitchin, N., Bailey, R., Liau, K., Lagkadinou, E., Türeci, Ö., Şahin, U., Xu, X., Dychter, S.S., Lu, C., Gentile, T., Gruber, W.
Publicado 2021

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

por Infante, Jeffrey R, Korn, Ronald L, Rosen, Lee S, LoRusso, Patricia, Dychter, Samuel S, Zhu, Joy, Maneval, Daniel C, Jiang, Ping, Shepard, H Michael, Frost, Gregory, Von Hoff, Daniel D, Borad, Mitesh J, Ramanathan, Ramesh K
Publicado 2018

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

por Infante, Jeffrey R, Korn, Ronald L, Rosen, Lee S, LoRusso, Patricia, Dychter, Samuel S, Zhu, Joy, Maneval, Daniel C, Jiang, Ping, Shepard, H Michael, Frost, Gregory, Von Hoff, Daniel D, Borad, Mitesh J, Ramanathan, Ramesh K
Publicado 2018

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

por Rosengren, Sanna, Dychter, Samuel S., Printz, Marie A., Huang, Lei, Schiff, Richard I., Schwarz, Hans-Peter, McVey, John K., Drake, Fred H., Maneval, Dan C., Kennard, Don A., Frost, Gregory I., Sugarman, Barry J., Muchmore, Douglas B.
Publicado 2015

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial

por Thomas, Stephen J., Perez, John L., Lockhart, Stephen P., Hariharan, Subramanian, Kitchin, Nicholas, Bailey, Ruth, Liau, Katherine, Lagkadinou, Eleni, Türeci, Özlem, Şahin, Ugur, Xu, Xia, Koury, Kenneth, Dychter, Samuel S., Lu, Claire, Gentile, Teresa C., Gruber, William C.
Publicado 2022

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

por Moreira, Edson D., Kitchin, Nicholas, Xu, Xia, Dychter, Samuel S., Lockhart, Stephen, Gurtman, Alejandra, Perez, John L., Zerbini, Cristiano, Dever, Michael E., Jennings, Timothy W., Brandon, Donald M., Cannon, Kevin D., Koren, Michael J., Denham, Douglas S., Berhe, Mezgebe, Fitz-Patrick, David, Hammitt, Laura L., Klein, Nicola P., Nell, Haylene, Keep, Georgina, Wang, Xingbin, Koury, Kenneth, Swanson, Kena A., Cooper, David, Lu, Claire, Türeci, Özlem, Lagkadinou, Eleni, Tresnan, Dina B., Dormitzer, Philip R., Şahin, Uğur, Gruber, William C., Jansen, Kathrin U.
Publicado 2022